METTL3 and metabolic dysfunction-associated steatotic liver disease: Collectively, these data support the notion that targeting METTL3 in conjunction with ICIs may provide therapeutic benefits across multiple cancer types, including CRC, TNBC, NAFLD-HCC, and melanoma.